Cargando…

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects

Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens for eradicating Helicobacter pylori. This study compared the pharmacokinetic and safety profile of tegoprazan and clarithromycin between combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Minkyung, Lee, Heechan, Kim, Seokuee, Kim, Bongtae, Song, Geun Seog, Shin, Jae-Gook, Ghim, Jong-Lyul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333645/
https://www.ncbi.nlm.nih.gov/pubmed/37440779
http://dx.doi.org/10.12793/tcp.2023.31.e11
_version_ 1785070707711934464
author Oh, Minkyung
Lee, Heechan
Kim, Seokuee
Kim, Bongtae
Song, Geun Seog
Shin, Jae-Gook
Ghim, Jong-Lyul
author_facet Oh, Minkyung
Lee, Heechan
Kim, Seokuee
Kim, Bongtae
Song, Geun Seog
Shin, Jae-Gook
Ghim, Jong-Lyul
author_sort Oh, Minkyung
collection PubMed
description Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens for eradicating Helicobacter pylori. This study compared the pharmacokinetic and safety profile of tegoprazan and clarithromycin between combination therapy and monotherapy to evaluate the potential drug-drug interaction. An open-label, randomized, 6-sequence, 3-period crossover study was conducted in 24 healthy subjects. According to the assigned sequence, the subject was administered the assigned treatment during 5 days in each period. PK parameters of tegoprazan and clarithromycin administered in combination were compared with those of the respective monotherapies. The co-administration of tegoprazan with clarithromycin increased maximum steady-state plasma concentration (C(ss,max)) and area under the plasma concentration-time curve in dosing interval at steady-state (AUC(ss,tau)) of tegoprazan (1.6-fold in C(ss,max) and 2.5-fold in AUC(ss,tau)) and M1 (2.0-fold in C(ss,max), 2.5-fold in AUC(ss,tau)) than tegoprazan alone. The C(ss,max) and AUC(ss,tau) of 14-hydroxyclarithromycin increased 1.8- and 2.0-fold in co-administration, respectively. The AUC(ss.tau) of clarithromycin was slightly increased in co-administration, but C(ss,max) was not changed. Combination of tegoprazan and clarithromycin and those of the respective monotherapies were tolerated in 24 healthy subjects. There may exist drug interaction that lead to reciprocal increase in plasma drug concentrations when tegoprazan and clarithromycin were administrated in combination and no safety concerns were raised. It is suggested that an in-depth analysis of the concentration-response relationship is necessary to determine whether these concentration changes warrant clinical action. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02052336
format Online
Article
Text
id pubmed-10333645
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Korean Society for Clinical Pharmacology and Therapeutics
record_format MEDLINE/PubMed
spelling pubmed-103336452023-07-12 Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects Oh, Minkyung Lee, Heechan Kim, Seokuee Kim, Bongtae Song, Geun Seog Shin, Jae-Gook Ghim, Jong-Lyul Transl Clin Pharmacol Original Article Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens for eradicating Helicobacter pylori. This study compared the pharmacokinetic and safety profile of tegoprazan and clarithromycin between combination therapy and monotherapy to evaluate the potential drug-drug interaction. An open-label, randomized, 6-sequence, 3-period crossover study was conducted in 24 healthy subjects. According to the assigned sequence, the subject was administered the assigned treatment during 5 days in each period. PK parameters of tegoprazan and clarithromycin administered in combination were compared with those of the respective monotherapies. The co-administration of tegoprazan with clarithromycin increased maximum steady-state plasma concentration (C(ss,max)) and area under the plasma concentration-time curve in dosing interval at steady-state (AUC(ss,tau)) of tegoprazan (1.6-fold in C(ss,max) and 2.5-fold in AUC(ss,tau)) and M1 (2.0-fold in C(ss,max), 2.5-fold in AUC(ss,tau)) than tegoprazan alone. The C(ss,max) and AUC(ss,tau) of 14-hydroxyclarithromycin increased 1.8- and 2.0-fold in co-administration, respectively. The AUC(ss.tau) of clarithromycin was slightly increased in co-administration, but C(ss,max) was not changed. Combination of tegoprazan and clarithromycin and those of the respective monotherapies were tolerated in 24 healthy subjects. There may exist drug interaction that lead to reciprocal increase in plasma drug concentrations when tegoprazan and clarithromycin were administrated in combination and no safety concerns were raised. It is suggested that an in-depth analysis of the concentration-response relationship is necessary to determine whether these concentration changes warrant clinical action. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02052336 Korean Society for Clinical Pharmacology and Therapeutics 2023-06 2023-06-27 /pmc/articles/PMC10333645/ /pubmed/37440779 http://dx.doi.org/10.12793/tcp.2023.31.e11 Text en Copyright © 2023 Translational and Clinical Pharmacology https://creativecommons.org/licenses/by-nc/4.0/It is identical to the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original Article
Oh, Minkyung
Lee, Heechan
Kim, Seokuee
Kim, Bongtae
Song, Geun Seog
Shin, Jae-Gook
Ghim, Jong-Lyul
Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title_full Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title_fullStr Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title_full_unstemmed Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title_short Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
title_sort evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333645/
https://www.ncbi.nlm.nih.gov/pubmed/37440779
http://dx.doi.org/10.12793/tcp.2023.31.e11
work_keys_str_mv AT ohminkyung evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT leeheechan evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT kimseokuee evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT kimbongtae evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT songgeunseog evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT shinjaegook evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects
AT ghimjonglyul evaluationofpharmacokineticdrugdruginteractionbetweentegoprazanandclarithromycininhealthysubjects